直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 117184
著者
Okada, M Sakamoto Hospital
板東, 浩 Sakamoto Hospital|Tokushima University|Japan Low Carbohydrate Diet Promotion Association KAKEN研究者をさがす
Iwatsuki, N Sakamoto Hospital
Ogawa, T Sakamoto Hospital
Sakamoto, K Sakamoto Hospital
キーワード
Oral semaglutide
Imeglimin
Twymeeg
Macrocytic anemia
Trial for Imeglimin Efficacy and Safety (TIMES)
資料タイプ
学術雑誌論文
抄録
Background: Oral semaglutide (imeglimin) has been prescribed for patients with type 2 diabetes (T2D) as Twymeeg.
Case presentation: The patient is 77-year-old male with hypertension, previous cerebral vascular accident (CVA). He continued unbalanced meal with preference of much carbohydrate. In Sept 2021, he became diabetic with HbA1c 8.8%.
Results: Imeglimin 2000mg/day was started improving to 6.7% for 2 months.
Discussion: Complete blood count (CBC) showed decreased Hb and increased MCV, suggesting macrocytic anemia for lack of vegetables. Much carbohydrate intake may bring T2D. Remarkable diabetic improvement may be from dual mechanisms for increasing insulin secretion and decreasing insulin resistance.
掲載誌名
SunText Review of Medical & Clinical Research
ISSN
27664813
出版者
SunText Reviews
3
2
開始ページ
155
発行日
2022-05-12
権利情報
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系